Target Molecule Generation With Hybrid Optimization and Toxicity Feedback

The patent creates virtual copies of molecules through computational generation in latent space, allowing extensive molecular exploration and validation without physical laboratory work. The generated molecules are evaluated through computational models before any experimental work, dramatically reducing the time and resources needed for initial drug discovery stages.

The patent performs preliminary molecular generation, optimization, and evaluation computationally before any experimental validation. By pre-screening thousands of generated molecules for desired properties and toxicity in silico, the system identifies only the most promising candidates for laboratory testing, significantly accelerating the overall discovery process.

The patent introduces gradient estimation techniques as intermediaries that bridge the differentiable VAE architecture and non-differentiable oracle functions. By approximating gradients for non-differentiable objectives through finite differences or other estimation methods, the system enables end-to-end optimization through the entire pipeline including toxicity predictions and property evaluations that would otherwise be incompatible with gradient-based training.

The patent modifies the optimization approach by changing from strict gradient-based optimization to gradient-estimation-based optimization. This parameter change in the optimization methodology allows the system to handle non-differentiable oracles while maintaining the benefits of latent space optimization through VAEs, effectively combining both requirements.

The patent dynamically switches between gradient-based optimization (for efficiency) and evolutionary algorithms or other gradient-free methods (for effectiveness in complex landscapes). By adapting the optimization strategy based on the specific property being optimized and the complexity of the landscape, the system achieves both high efficiency and high effectiveness across diverse molecular properties.

The patent merges gradient-based optimization with evolutionary algorithms and other optimization techniques into a hybrid framework. This combination allows the system to leverage the speed of gradient methods for simple properties while using more robust but slower methods for complex non-linear properties, achieving both efficiency and effectiveness.

The patent incorporates toxicity evaluation as a feedback mechanism in the molecular generation process. Generated molecules are evaluated for toxicity through computational models, and this toxicity information feeds back into the optimization process to guide the generation of safer molecules. This continuous feedback loop ensures that toxicity considerations are integrated throughout the discovery process rather than being an afterthought.

The patent performs preliminary toxicity assessment and counteracts potential harmful effects by optimizing for low toxicity during the generation phase itself. By anticipating and preventing toxicity issues before they manifest, the system generates molecules that are inherently safer, rather than requiring post-generation filtering or remediation.